



دلالة الصحية

Dallah Health

DALLAH HEALTHCARE COMPANY

(A Saudi Joint Stock Company)

CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

(UNAUDITED)

For the three-month period ended 31 March 2026

together with the

INDEPENDENT AUDITOR'S REVIEW REPORT

DALLAH HEALTHCARE COMPANY “A Saudi Joint Stock Company”
CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED)
For the three-month period ended 31 March 2026

Contents	Page(s)
Independent Auditor’s report on review of condensed consolidated interim financial statements	1
Condensed Consolidated Interim Financial Statements:	
Condensed consolidated interim statement of financial position	2
Condensed consolidated interim statement of profit or loss	3
Condensed consolidated interim statement of comprehensive income	4
Condensed consolidated interim statement of changes in equity	5
Condensed consolidated interim statement of cash flows	6
Notes to the condensed consolidated interim financial statements	7-18



KPMG Professional Services Company

Roshn Front, Airport Road
P. O. Box 92876
Riyadh 11663
Kingdom of Saudi Arabia
Commercial Registration No. 10104245494

Headquarters in Riyadh

شركة كي بي إم جي للاستشارات المهنية مساهمة مهنية

واجهة روشن، طريق المطار
صندوق بريد ٩٢٨٧٦
الرياض ١١٦٦٣
المملكة العربية السعودية
رقم سجل تجاري ١٠١٠٤٢٤٥٤٩٤

المركز الرئيسي في الرياض

Independent auditor's report on review of condensed consolidated interim financial statements

To the Shareholders of Dallah Healthcare Company (Saudi Joint Stock Company)

Introduction

We have reviewed the accompanying 31 March 2026 condensed consolidated interim financial statements of **Dallah Healthcare Company ("the Company") and its subsidiaries ("the Group")** which comprises:

- the condensed consolidated interim statement of financial position as at 31 March 2026;
- the condensed consolidated interim statement of profit or loss for the three-month period ended 31 March 2026;
- the condensed consolidated interim statement of comprehensive income for the three-month period ended 30 March 2026;
- the condensed consolidated interim statement of changes in equity for the three-month period ended 31 March 2026;
- the condensed consolidated interim statement of cash flows for the three-month period ended 31 March 2026; and
- the notes to the condensed consolidated interim financial statements.

Management is responsible for the preparation and presentation of these condensed consolidated interim financial statements in accordance with IAS 34, 'Interim Financial Reporting' that is endorsed in the Kingdom of Saudi Arabia. Our responsibility is to express a conclusion on these condensed consolidated interim financial statements based on our review.

Scope of Review

We conducted our review in accordance with the International Standard on Review Engagements 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity' that is endorsed in the Kingdom of Saudi Arabia. A review of interim financial statements consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with International Standards on Auditing that are endorsed in the Kingdom of Saudi Arabia, and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Conclusion

Based on our review, nothing has come to our attention that causes us to believe that the accompanying 31 March 2026 condensed consolidated interim financial statements of **Dallah Healthcare Company and its subsidiaries** are not prepared, in all material respects, in accordance with IAS 34, 'Interim Financial Reporting' that is endorsed in the Kingdom of Saudi Arabia.

KPMG Professional Services Company



Fahad Mubark Al Dossari
License No: 469

Riyadh on: 27 Dhul Qidah I 1447H
Corresponding to: 14 May 2026



© 2026 KPMG Professional Services Company, a professional closed joint stock company registered in the Kingdom of Saudi Arabia with a paid-up capital of SAR110,000,000 and a non-partner member firm of the KPMG global organization of independent member firms affiliated with KPMG International Limited, a private English company limited by guarantee. All rights reserved.

© ٢٠٢٦ شركة كي بي إم جي للاستشارات المهنية مساهمة مهنية، شركة مساهمة مهنية منقولة مسجلة في المملكة العربية السعودية، رأس مالها (١١٠,٠٠٠,٠٠٠) ريال سعودي مدفوع بالكامل، وهي عضو غير شريك في الشبكة العالمية لشركات كي بي إم جي المستقلة والتابعة لـ كي بي إم جي العالمية المحدودة، شركة انجليزية خاصة محدودة بالضمان. جميع الحقوق محفوظة.

DALLAH HEALTHCARE COMPANY “A Saudi Joint Stock Company”
CONDENSED CONSOLIDATED INTERIM STATEMENT OF FINANCIAL POSITION
(All amounts in Saudi Riyals unless otherwise stated)


	Notes	As of 31 March 2026 (Unaudited)	As of 31 December 2025 (Audited)
ASSETS			
Non-current assets			
Property and equipment	5	4,577,639,450	4,480,247,213
Right-of-use assets		163,980,306	171,676,156
Intangible assets and goodwill		702,652,290	704,495,008
Equity-accounted investees	6	1,844,456,640	1,833,559,643
Financial assets at fair value through other comprehensive income		939,741	875,932
Total non-current assets		7,289,668,427	7,190,853,952
Current assets			
Inventories		373,285,309	359,678,478
Prepayments and other current assets		178,771,404	162,209,193
Due from related parties and others		6,749,340	6,649,339
Unbilled revenue		13,296,958	8,926,101
Trade receivables	8	1,262,908,419	1,196,422,012
Cash and cash equivalents		187,416,957	210,565,408
Total current assets		2,022,428,387	1,944,450,531
Total assets		9,312,096,814	9,135,304,483
EQUITY AND LIABILITIES			
Equity			
Share capital	1,2d	1,015,747,690	1,015,747,690
Share premium	1,2d	1,475,976,054	1,475,976,054
Statutory reserve		93,614,972	93,614,972
Treasury shares	1	(89,568,856)	(74,021,614)
Retained earnings		1,608,289,949	1,574,320,480
Fair value reserve		(3,188,399)	(3,252,208)
Equity attributable to owners of the Company		4,100,871,410	4,082,385,374
Non-controlling interests		38,406,223	37,645,990
Total equity		4,139,277,633	4,120,031,364
LIABILITIES			
Non-current liabilities			
Long-term Murabaha financing	9	2,984,976,705	2,942,933,467
Long-term lease liabilities		117,532,278	125,950,619
Employee benefits		388,950,163	374,341,690
Long-term payables		1,569,824	1,424,772
Total Non-current liabilities		3,493,028,970	3,444,650,548
Current liabilities			
Short-term Murabaha financing	9	670,110,218	615,413,564
Current portion of long-term Murabaha financing	9	203,529,611	204,235,856
Short-term lease liabilities		42,211,713	45,490,047
Trade payables and others		429,359,886	410,047,867
Due to related parties and others		1,126,133	1,921,495
Accrued expenses and other current liabilities		258,271,819	271,585,715
Provision for zakat	10	24,629,357	21,928,027
Dividends payable	15	50,551,474	--
Total current liabilities		1,679,790,211	1,570,622,571
Total liabilities		5,172,819,181	5,015,273,119
Total equity and liabilities		9,312,096,814	9,135,304,483

The accompanying notes from 1 to 18 form an integral part of these condensed consolidated interim financial statements

CFO
Amine Hariz



CEO
Ahmad Saleh Babaeer



CHAIRMAN
Tarek Othman Alkasabi



DALLAH HEALTHCARE COMPANY "A Saudi Joint Stock Company"
CONDENSED CONSOLIDATED INTERIM STATEMENT OF PROFIT OR LOSS
(All amounts in Saudi Riyals unless otherwise stated)


	Notes	For the three-month period ended 31 March	
		2026 (Unaudited)	2025 (Unaudited)
Revenue	11	1,013,262,268	832,752,814
Cost of revenue		(679,179,645)	(535,142,985)
Gross profit		334,082,623	297,609,829
Selling and marketing expenses		(21,506,346)	(23,714,203)
General and administrative expenses		(190,684,579)	(141,816,937)
Impairment loss on trade receivables	8	(12,169,446)	(12,142,108)
Other income		10,634,899	57,954,863
Operating profit		120,357,151	177,891,444
Finance cost		(43,271,642)	(26,195,260)
Group share of results from equity accounted investees	6	10,896,997	9,100,144
Profit for the period before zakat		87,982,506	160,796,328
Zakat	10	(2,701,330)	(4,025,692)
Profit for the period		85,281,176	156,770,636
Profit for the period attributable to:			
Owners of the Company		84,520,943	155,560,410
Non-controlling interests		760,233	1,210,226
		85,281,176	156,770,636
Basic and diluted earnings per share	12	0.84	1.59

The accompanying notes from 1 to 18 form an integral part of these condensed consolidated interim financial statements

CFO
Amine Hariz



CEO
Ahmad Saleh Babacer



CHAIRMAN
Tarek Othman Alkasabi



DALLAH HEALTHCARE COMPANY “A Saudi Joint Stock Company”
CONDENSED CONSOLIDATED INTERIM STATEMENT OF COMPREHENSIVE INCOME
 (All amounts in Saudi Riyals unless otherwise stated)


	For the three-month period ended 31 March	
	2026 (Unaudited)	2025 (Unaudited)
Profit for the period	<u>85,281,176</u>	<u>156,770,636</u>
Other comprehensive income:		
<u>Items that will not be reclassified to profit or loss</u>		
Gain / (loss) of evaluation of financial assets at fair value through other comprehensive income	<u>63,809</u>	<u>(71,719)</u>
Other comprehensive income / (loss) for the period	<u>63,809</u>	<u>(71,719)</u>
Total comprehensive income for the period	<u>85,344,985</u>	<u>156,698,917</u>
Total comprehensive income for the period attributable to:		
Owners of the Company	<u>84,584,752</u>	<u>155,488,691</u>
Non-controlling interests	<u>760,233</u>	<u>1,210,226</u>
	<u>85,344,985</u>	<u>156,698,917</u>

The accompanying notes from 1 to 18 form an integral part of these condensed consolidated interim financial statements

CFO
Amine Hariz



CEO
Ahmad Saleh Babaeer



CHAIRMAN
Tarek Othman Alkasabi



DALLAH HEALTHCARE COMPANY "A Saudi Joint Stock Company"
CONDENSED CONSOLIDATED INTERIM STATEMENT OF CHANGES IN EQUITY

(All amounts in Saudi Riyals unless otherwise stated)

	Share capital	Share premium	Statutory reserve	Treasury Shares	Retained earnings	Fair value reserve	Total shareholders' equity	Non-controlling interests	Total equity
For the period ended 31 March 2026 (Unaudited)									
As at 1 January 2026	1,015,747,690	1,475,976,054	93,614,972	(74,021,614)	1,574,320,480	(3,252,208)	4,082,385,374	37,645,990	4,120,031,364
Profit for the period	--	--	--	--	84,520,943	--	84,520,943	760,233	85,281,176
Other comprehensive income for the period	--	--	--	--	--	63,809	63,809	--	63,809
Total comprehensive income for the period					84,520,943	63,809	84,584,752	760,233	85,344,985
Transactions with owners of the Company:									
Purchase of treasury shares (Note 1)	--	--	--	(15,547,242)	--	--	(15,547,242)	--	(15,547,242)
Dividends (Note 15)	--	--	--	--	(50,551,474)	--	(50,551,474)	--	(50,551,474)
As at 31 March 2026	1,015,747,690	1,475,976,054	93,614,972	(89,568,856)	1,608,289,949	(3,188,399)	4,100,871,410	38,406,223	4,139,277,633
For the period ended 31 March 2025 (Unaudited)									
As at 1 January 2025	976,811,660	1,027,432,988	93,614,972	(60,455,136)	1,434,282,423	(3,130,637)	3,468,556,270	278,463,658	3,747,019,928
Profit for the period	--	--	--	--	155,560,410	--	155,560,410	1,210,226	156,770,636
Other comprehensive loss for the period	--	--	--	--	--	(71,719)	(71,719)	--	(71,719)
Total comprehensive income for the period					155,560,410	(71,719)	155,488,691	1,210,226	156,698,917
Transactions with owners of the Company:									
Capital increase (Note 1,2d)	38,936,030	--	--	--	--	--	38,936,030	--	38,936,030
Share premium increase (Note 1,2d)	--	448,543,066	--	--	--	--	448,543,066	--	448,543,066
Dividends (Note 15)	--	--	--	--	(50,598,609)	--	(50,598,609)	--	(50,598,609)
Changes in ownership interest:									
Movement in non-controlling interest (Note 2d)	--	--	--	--	--	--	--	(1,024,000)	(1,024,000)
Non-controlling interest on the date of acquisition of subsidiaries (Note 2d)	--	--	--	--	--	--	--	4,583,834	4,583,834
As at 31 March 2025	1,015,747,690	1,475,976,054	93,614,972	(60,455,136)	1,539,244,224	(3,202,356)	4,060,925,448	283,233,718	4,344,159,166

The accompanying notes from 1 to 18 form an integral part of these condensed consolidated interim financial statements

CFO
Amine Hariz

CEO
Ahmad Saleh Babacer

CHAIRMAN
Tarek-Ottman Alkasabi

DALLAH HEALTHCARE COMPANY "A Saudi Joint Stock Company"
CONDENSED CONSOLIDATED INTERIM STATEMENT OF CASH FLOWS
(All amounts in Saudi Riyals unless otherwise stated)

	Notes	For the Three-month period ended	
		31 March	
		2026 (Unaudited)	2025 (Unaudited)
CASH FLOWS FROM OPERATING ACTIVITIES			
Profit for the period		85,281,176	156,770,636
<i>Adjustments:</i>			
Depreciation on property and equipment	5	48,824,469	35,273,759
Depreciation on right-of-use assets		11,339,404	8,303,705
Amortization on intangible assets and goodwill		2,605,318	1,495,521
Employee benefits charge		18,956,065	20,162,796
Provision (reversal) of write-downs of inventories to net realizable value		1,110,994	(222,769)
Impairment loss on prepayments and other current assets		338,922	--
Group share of results from equity accounted investees	6	(10,896,997)	(9,100,144)
Impairment loss on trade receivables	8	12,169,446	12,142,108
Gains resulting from valuation of in-kind consideration in a real estate fund	6	--	(51,434,877)
Loss on sale of property and equipment		582,964	148,842
Zakat charge	10	2,701,330	4,025,692
Finance cost		43,271,642	26,195,260
<i>Changes in operating assets and liabilities:</i>			
Inventories		(14,717,825)	(34,254,319)
Unbilled revenue		(4,370,857)	5,284,263
Trade receivables		(78,655,853)	110,365,480
Prepayments and other current assets		(16,901,133)	9,781,165
Related parties and others, net		(895,363)	(12,134,754)
Trade payables		19,312,019	34,699,721
Accrued expenses and other current liabilities		(13,313,896)	(30,894,237)
Cash generated from operating activities		106,741,825	286,607,848
Zakat paid	10	--	(4,926,346)
Employees' benefits paid		(4,347,594)	(7,788,668)
Net cash generated from operating activities		102,394,231	273,892,834
CASH FLOWS FROM INVESTING ACTIVITIES			
Acquisition of property and equipment	5	(148,008,476)	(165,120,656)
Acquisition of intangible assets		(322,600)	(751,656)
Proceeds from disposal of property and equipment		768,806	--
Acquisition of subsidiaries, net of cash acquired		--	(313,820,558)
Acquisition of equity-accounted investees - cash consideration	6	--	(8,695,370)
Dividends received from equity-accounted investees	6	--	1,020,000
Net cash used in investing activities		(147,562,270)	(487,368,240)
CASH FLOWS FROM FINANCING ACTIVITIES			
Proceeds from Murabaha financing	9	345,670,575	507,484,520
Repayment of Murabaha financing	9	(249,636,928)	(246,126,851)
Payment of lease liabilities		(18,543,139)	(11,205,767)
Acquisition of non-controlling interest	2d	--	(1,024,000)
Purchase of treasury shares	1	(15,547,242)	--
Long-term payable		145,052	(130,449)
Finance cost paid		(40,068,730)	(26,725,703)
Net cash generated from financing activities		22,019,588	222,271,750
Net change in cash and cash equivalents		(23,148,451)	8,796,344
Cash and cash equivalents at the beginning of the period		210,565,408	166,324,649
Cash and cash equivalents at the end of the period		187,416,957	175,120,993

The accompanying notes from 1 to 18 form an integral part of these condensed consolidated interim financial statements

CFO
Amine Hariz



CEO
Ahmad Saleh Babacer



CHAIRMAN
Tarek Othman Alkasabi



DALLAH HEALTHCARE COMPANY “A Saudi Joint Stock Company”
NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
(For the three-month period ended 31 March 2026) (unaudited)
(All amounts in Saudi Riyals unless otherwise stated)

1. REPORTING ENTITY

Dallah Healthcare Company (the “Company”) was established as a Limited Liability Company, registered in the Kingdom of Saudi Arabia under unified number 7001473425 dated 13 Rabi Al-Akhar 1415H (corresponding to 18 September 1994).

On 14 Jumada Al-Awwal 1429H (corresponding to 20 May 2008), the Company’s Board of Directors converted Dallah Healthcare Company as a Saudi Closed Joint Stock Company. The Company became a listed Company in the Saudi Capital Market on 04 Safar 1434H (corresponding to 17 December 2012). The name of the Company was changed from "Dallah Healthcare Holding Company" to "Dallah Healthcare Company" based on the approval of Extraordinary General Assembly held on 16 Safar 1438H (corresponding to 16 November 2016) after completion of all legal formalities.

The objectives of the Company include operate, manage and maintain the healthcare entities, wholesale medicines and retail of medical and surgical equipment, prosthetics and devices for the disabled, hospital equipment and manufacturing medicines, pharmaceuticals, herbals, health, cosmetics, detergents, disinfectants and packaging in the Kingdom of Saudi Arabia.

On 15 Jumada al-Thani 1445 H (corresponding to 28 December 2023), the Company’s extraordinary general assembly meeting approved in amending the company’s By-laws to comply with the requirement of new companies' law.

The Company’s registered office is located at King Fahad Road, Riyadh, Kingdom of Saudi Arabia.

Share Capital & Share premium.

The authorized, issued and paid-up share capital of the Company is SR 1,015,747,690 (31 December 2025: SR 1,015,747,690) consisting of 101,574,769 shares (31 December 2025: 101,574,769) of SR 10 each.

On 23 Ramadan, 1446H (corresponding to 23 March 2025) the Company issued 3,893,603 new ordinary shares in favour of Ayyan Investment Company to acquire 100% of the shares of Al Salam Medical Services Company “Currently named Dallah Al Khobar hospital company” and to acquire 97.41% of the shares of Al-Ahsa Medical Services Company and, resulted in increasing share capital from SR 976,811,660 to SR 1,015,747,690, This resulted in a recording of additional share premium amounting SR 448,543,066 million. The share premium balance reached SR 1,475,976,054 million. The company has completed all amendments to its Articles of Association and commercial registration.

On 15 Ramadan 1447H (corresponding to 04 March 2026), the Company’s Board of Directors recommended to the Extraordinary General Assembly to increase the Company’s share capital through the issuance of bonus shares at a rate of 20% of the Company’s share capital before the increase. Accordingly, the number of the shares after the increase will be SR 121,889,723 shares. The Company’s share capital after the increase will also become SR 1,218,897,230 instead of SR 1,015,747,690 before the increase. The share capital will be increased by SR 93,614,972 from the statutory reserve and SR 109,534,568 from the share premium. This recommendation remains subject to obtaining the approval of the relevant authorities and the Company’s Extraordinary General Assembly, which has not yet been convened.

Dallah Al Baraka Holding Company (the ultimate parent company), a closed Saudi joint stock company, owns 47.4% of the Company's share capital, as of the date of these financial statements.

Treasury shares

On 15 Jumada al-Thani 1445 H (corresponding to 28 December 2023), the Company’s extraordinary general assembly meeting approved the Company’s shares buy-back up to 3,826,189 shares to be used for financing acquisition transactions. On 27 Rabi’ Al-Thani 1447H (corresponding to 19 October 2025), the Extraordinary General Assembly approved changing the purpose of the share purchase to be for the Employee Incentive Program with a maximum of 1,000,000 shares.

As of 31 March 2026, the Company had repurchased 607,819 treasury shares which is allocated to Employee Incentive Program at a total cost of SAR 89,568,856 (31 December 2025: 471,821 shares at a total cost of SAR 74,021,614).

BASIS OF ACCOUNTING

a) Statement of compliance

These condensed consolidated interim financial statements comprise the interim financial statements of the Company and its subsidiaries (together referred to as the ‘Group’).

These condensed consolidated interim financial statements have been prepared in accordance with IAS 34 ‘Interim Financial Reporting’ that are endorsed in the Kingdom of Saudi Arabia (KSA) and other standards and pronouncements issued by the Saudi Organization for Chartered and Professional Accountants (SOCPA).

The condensed consolidated interim financial statements do not include all of the information and disclosures required for full annual consolidated financial statements and should be read in conjunction with Group’s last annual consolidated financial statements as at and for the year ended 31 December 2025. Selected explanatory notes are included to explain events and transactions that are significant to an understanding of the changes in the Group’s financial position and performance since the last annual consolidated financial statements.

DALLAH HEALTHCARE COMPANY “A Saudi Joint Stock Company”
NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
(For the three-month period ended 31 March 2026) (unaudited)
(All amounts in Saudi Riyals unless otherwise stated)

b) Basis of preparation

These condensed consolidated interim financial statements have been prepared on a going concern basis under accrual basis of accounting and the historical cost convention except for:

- the employees’ end of service benefit obligations which are measured using the projected unit credit method and;
- financial assets at fair value through other comprehensive income which are measured at fair value;

c) Functional and presentation currency

These condensed consolidated interim financial statements are presented in Saudi Arabian Riyals (SR) which is also the Group’s functional currency.

d) Basis of consolidation

The subsidiary companies (referred to as the “Subsidiaries”) incorporated into these condensed consolidated interim financial statements are as follows:

Name of subsidiaries	Share in equity%		Country of operation and Commercial registration	Principal activity	Capital (SR)
	31 March 2026	31 December 2025			
Dallah Pharma Company LLC *	100%	100%	Kingdom of Saudi Arabia, Commercial registration No. 1010410613	Pharmaceutical, herbal & cosmetic distribution & manufacturing.	4,000,000
Afyaa Al-Nakheel for Supporting Services Company LLC	100%	100%	Kingdom of Saudi Arabia, Commercial registration No.1010404576	Provide manpower & Support services to hospitals and medical centres.	50,000
Dallah Namar Hospital Health Company LLC	100%	100%	Kingdom of Saudi Arabia, Commercial registration No.1010495218	Operating, managing, equipping and developing hospitals and healthcare facilities, medical polyclinics.	5,000,000
Dallah Medical Care Company LLC “Dallah Clinics”	100%	100%	Kingdom of Saudi Arabia, Commercial Registration No. 1010189420	Providing of medical services – Medical Clinic	100,000
Dallah Medical Care Company LLC “Dallah Pharmacies”	99%	99%	Kingdom of Saudi Arabia, Commercial registration No. 1010962080	Sale of pharmaceutical and medical products, cosmetics and toiletries	50,000
Makkah Medical Center Company (Closed Joint Stock Company) **	91.93%	91.93%	Kingdom of Saudi Arabia, Commercial registration No. 4031021286	Practicing the activity of public hospitals	120,080,000
Care Shield Holding Company (Closed Joint Stock Company) ***	100%	100%	Kingdom of Saudi Arabia, Commercial registration No.1010379441	Managing private hospitals, medical and diagnostic centres, and an analytical laboratory, providing medical services, purchasing lands to build buildings on, and investing these buildings by sale or rent for the benefit of the Company.	125,000,000
Dallah Al Khobar hospital company (Closed Joint Stock Company) ****	100%	100%	Kingdom of Saudi Arabia, Commercial Registration No. 2051059611	Operating and managing hospitals	200,000,000
Al-Ahsaa Medical Service company (Closed Joint Stock Company) *****	97.41%	97.41%	Kingdom of Saudi Arabia, Commercial Registration No. 2252025213	Operating and managing hospitals	150,000,000

DALLAH HEALTHCARE COMPANY “A Saudi Joint Stock Company”
NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
(For the three-month period ended 31 March 2026) (unaudited)
(All amounts in Saudi Riyals unless otherwise stated)

*** Dallah Pharma (Subsidiary)**

Subsequent to the financial statements, on 05 Dhu Al-Qi’dah 1447H (corresponding to 22 April 2026), Dallah Pharma Pharmaceuticals Factory (which was previously a branch of Dallah Pharma Company “a subsidiary”) was converted into a Simplified Joint Stock Company under the name Dallah Pharma Factory Company, and the required statutory and regulatory procedures were duly completed.

The share capital of Dallah Pharma Factory Company amounts to SAR 2,000,000, and it is 100% owned by Dallah Pharma Company “a subsidiary”.

**** Acquisition of non-controlling interest of Makkah Medical Center Company (Subsidiary)**

During the first quarter 2025, the Company purchased an additional 0.48% equity stake in Makkah Medical Center for a total value of SAR 1,024,000.

***** Acquisition of non-controlling interest of Care Shield Holding Company (Subsidiary)**

On 27 Jumada al-Akhirah 1447H (corresponding to 18 December 2025), the Company announces the signing of agreement to purchase all the remaining shares owned by Growth Avenue Investments Company (a single shareholder company), a limited liability company that is wholly-owned by Maharah Human Resources Company (a listed joint stock company) (“Growth Avenue”) representing 41.36% of the share capital of Care Shield Holding Company, resulting in Dallah Healthcare’s ownership of the full share capital of Care Shield Holding Company and the value of the deal amounted to SAR 434,311,080.

On 04 Rajab 1447H (corresponding to 24 December 2025), the transaction has been completed after the fulfilment of its condition and the transfer of shares in Care Shield has been transferred from Growth Avenue to Dallah Healthcare after the cash consideration was settled. The net consideration transferred for the transaction of SAR 434,311,080 and the non-controlling interest balance of SAR 243,036,670, amounting to SAR 191,274,410, was recognized in retained earnings for the Company.

- Care Shield Holding Company owns the following subsidiaries:

Subsidiaries

Medical Services Projects Company (“MSPC”)
Consulting Clinics Center Company Limited (“CCC”)
Modern Medical Initiative Company Limited (“MMI”)
Modern Clinics Pharmacy Company Limited (“MCP”)

Ownership percentage %

100%
100%
100%
99.99%

****** Acquisition of Dallah Al Khobar hospital company and Al-Ahsa Medical Services Company (Subsidiaries)**

On 15 Safar 1446H (corresponding to 19 August 2024), the Company signed a binding share purchase and subscription agreement with Ayyan Investment Company in connection with the purchase of its shares in Al Salam Medical Services Company (Currently named “Dallah Al Khobar hospital company”) (100%) of the Company capital (the owner of Al Salam hospital in Al-Khobar “Currently named Dallah Al Khobar hospital company”) and the purchase of Ayyan Investment Company shares in Al Ahsa Medical Services Company (97.41%) of the Company capital (the owner of Al Ahsa hospital in Al Ahsa “Currently named Dallah Al Ahsa”) by way of share swap in addition to a cash consideration to be paid in accordance with an agreed mechanism.

On 12 Ramadan 1446H (corresponding to 12 March 2025, (the Extraordinary General Assembly meeting approved to increase the Company’s capital from SR 976,811,660 to SR 1,015,747,690 thereby increasing the number of its shares from 97,681,166 ordinary shares to 101,574,769 ordinary shares, representing an increase of 3.99% in Dallah’s current capital, to acquire (a) all shares in Al-Salam Medical Services Company “Currently named Dallah Al Khobar hospital company”, totalling 20,000,000 ordinary shares with a nominal value of 10 SAR per share; and (b) 14,611,600 ordinary shares with a nominal value of 10 SAR per share in Al-Ahsa Medical Services Company, representing 97.41% of the shares in Al-Ahsa Medical Services Company from the seller, Ayyan Investment Company, in exchange for the issuance of 3,893,603 ordinary shares with a nominal value of 10 SAR per share, also it have been approved the amendments to Article (7) of Dallah health care’s bylaws regarding the capital. The new shares were issued on 23 March 2025 (being the acquisition date).

Subsequent to the financial statements, on 05 Dhu Al-Qi’dah 1447H (corresponding to 22 April 2026), the Company completed the acquisition of the non-controlling equity interest in Al Ahsa Medical Services Company, representing 2.59% of its share capital, for a total consideration of SAR 10,875,200. As a result, the Company subsequently owns 100% of the share capital of Al Ahsa Medical Services Company.

3. USE OF JUDGEMENTS AND ESTIMATES

The preparation of these condensed consolidated interim financial statements requires management to make judgments, estimates and assumptions that affect the application of Group’s accounting policies and the reported amounts of assets, liabilities, income and expenses, the actual results may differ from these estimates.

Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in future periods affected.

During the preparation of these condensed consolidated interim financial statements, there have been no changes in the significant judgements made by management in applying the Group’s accounting policies and the key sources of estimation and uncertainty from those which were applied to the annual audited consolidated financial statements of the Group for the year ended 31 December 2025.

The Group’s financial risk management objectives and policies and the methods to determine the fair values are consistent with those disclosed in the most recent annual consolidated financial statements for the year ended 31 December 2025.

The Group follows the practice of performing actuarial valuations of the provision for employees' benefits annually at the year end.

Measurement of fair values

A number of the Group’s accounting policies require the measurement of fair values, for both financial and non-financial assets and liabilities. The Group has an established control framework with respect to the measurement of fair values. This includes a valuation team that has overall responsibility for overseeing all significant fair value measurements, including Level 3 fair values, and reports directly to the chief financial officer.

The valuation team regularly reviews significant unobservable inputs and valuation adjustments. If third party information, such as broker quotes or pricing services, is used to measure fair values, then the valuation team assesses the evidence obtained from the third parties to support the conclusion that these valuations meet the requirements of the Standards, including the level in the fair value hierarchy in which the valuations should be classified.

When measuring the fair value of an asset or a liability, the Group uses market observable data as far as possible. Fair values are categorised into different levels in a fair value hierarchy based on the inputs used in the valuation techniques as follows:

- **Level 1:** Uses quoted prices (unadjusted) in active markets for identical assets or liabilities.
- **Level 2:** Uses inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly (i.e., as prices) or indirectly (i.e., derived from prices).
- **Level 3:** Uses inputs for the asset or liability that are not based on observable market data (unobservable inputs). If the inputs used to measure the fair value of an asset or a liability are categorised in different levels of the fair value hierarchy, then the fair value measurement is categorised in its entirety in the same level of the fair value hierarchy as the lowest level input that is significant to the entire measurement.

The Group recognises transfers between levels of the fair value hierarchy at the end of the reporting period during which the change has occurred.

Regional Geopolitical Developments

The recent regional military escalations have triggered a high-risk conflict environment across the Gulf. The situation is still very fluid, and scenarios can shift very quickly. The escalations have brought about additional uncertainties in the Company’s operating environment. With respect to financial statements for the period ended 31 March 2026, the potential financial reporting effects of the conflict are considered to be non-adjusting in nature.

The management has been closely monitoring the impact of the developments on the Company’s operation. As the situation is fast evolving and fluid, the effect of the escalations is subject to significant levels of uncertainty, with the full range of possible effects unknown.

4. THE MATERIAL ACCOUNTING POLICIES

The material accounting policies applied and method of computation adopted for preparation of these condensed consolidated interim financial statements are consistent with those that were applied in the Group’s last annual consolidated financial statements as at and for the year ended 31 December 2025.

Accounting standards issued

A number of new accounting standards and amendments are effective starting from 1 January 2026, which have been disclosed in the Group’s last annual consolidated financial statements. These amendments and standards did not have a material impact on these condensed consolidated interim financial statements.

5. PROPERTY AND EQUIPMENT

	31 March 2026 (Unaudited)	31 December 2025 (Audited)
Cost:		
Balance at the beginning of the period / year	6,032,312,912	4,306,746,429
Resulting from the acquisition of subsidiaries	--	1,281,420,396
Additions during the period / year	148,008,476	465,287,560
Disposals during the period / year	(2,107,771)	(16,950,874)
Transfer to intangible assets and goodwill	(440,000)	(4,190,599)
Balance at the end of the period / year	6,177,773,617	6,032,312,912
Accumulated Depreciation:		
Balance at the beginning of the period / year	1,552,065,699	1,133,816,182
Resulting from the acquisition of subsidiaries	--	262,571,347
Charge during the period / year	48,824,469	171,585,653
Disposals during the period / year	(756,001)	(15,765,092)
Transfer to intangible assets and goodwill	--	(142,391)
Balance at the end of the period / year	1,600,134,167	1,552,065,699
Net book value at the end of the period / year	4,577,639,450	4,480,247,213

Capital work in progress

The Group commenced a new project for a hospital on a land owned by the Group with an area of 45,000 square meters located in Al-Arid district in Riyadh. The hospital capacity of 250 beds and has the possibility of expansion in the future. In addition, the Group is continuously working on the expansions and improvements of the medical premises in the Group.

The projects under constructions amounting to SR 519 million as at 31 March 2026 (31 December 2025: SR 402 million).

During the period ended on 31 March 2026, the capitalized financing costs for Murabaha and lease liability on projects under constructions amounted to SR 5 million (31 December 2025: SR 21 million).

DALLAH HEALTHCARE COMPANY “A Saudi Joint Stock Company”
NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
(For the three-month period ended 31 March 2026) (unaudited)
(All amounts in Saudi Riyals unless otherwise stated)

6. EQUITY ACCOUNTED INVESTEEES

Equity accounted investees are as follows:

Associate Name	Classification	Ownership interest in equity as at		Country of operation and principal place of business	Movement of the investments				Group's share of profit for the three-month period ended 31 March 2025 (Unaudited)	Dividends received during the three-month period ended 31 March 2025 (Unaudited)
		31 March 2026	31 December 2025		Balance at 31 December 2025 (Audited)	Group's share of profit (loss) for the three-month period ended 31 March 2026 (Unaudited)	Dividends received during the three-month period ended 31 March 2026 (Unaudited)	Balance at 31 March 2026 (Unaudited)		
Dr. Mohammed Rashid Al-Faqih Company	Associate	31.21%	31.21%	Kingdom of Saudi Arabia	101,838,627	2,854,911	--	104,693,538	3,284,096	--
Meras Arabia Medical Holding Company	Associate	17%	17%	Kingdom of Saudi Arabia	53,945,667	3,739,363	--	57,685,030	3,719,498	1,020,000
MEFIC Private Equity Opportunities Fund 3	Associate	41.6%	41.6%	Kingdom of Saudi Arabia	101,935,541	6,016,240	--	107,951,781	1,500,000	--
International Medical Centre Company	Associate	27.18%	27.18%	Kingdom of Saudi Arabia	1,399,136,902	(3,519,589)	--	1,395,617,313	596,550	--
Wahet Al-Nakheel Real Estate Fund	Associate	33.33%	33.33%	Kingdom of Saudi Arabia	176,702,906	1,806,072	--	178,508,978	--	--
					1,833,559,643	10,896,997	--	1,844,456,640	9,100,144	1,020,000

DALLAH HEALTHCARE COMPANY “A Saudi Joint Stock Company”
NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
(For the three-month period ended 31 March 2026) (unaudited)
(All amounts in Saudi Riyals unless otherwise stated)

Dr. Mohammed Rashid Al-Faqih Company

The principal activity of Dr. Mohammed Rashid Al-Faqih Company is to own, operate and maintain the hospitals and health centres. Dr. Mohammed Rashid Al-Faqih Company owns a hospital in eastern Riyadh City under the name of Dr. Mohammed Al-Faqih Hospital.

On 13 Muharram 1442H (corresponding to 1 September 2020), the operation of the first phase of the hospital began. The hospital has a capacity of 350 beds.

On 19 Jumada al-Awwal 1447H (corresponding to 10 November 2025), the company has signed in acceptance of a non-binding offer presented by Fakeeh Hospital Company (Joint stock company) to purchase its entire shareholding of (31.21%) in the share capital of Dr. Mohammad Bin Rashed Al Fagih & Partners Company (“the Associate Company”).

Subsequent to the financial statements, on 18 Dhu Al-Qi’ dah 1447H (corresponding to 05 May 2026), the Company entered into a binding Sale and Purchase Agreement, pursuant to which the purchaser, Fakeeh Care Company, will acquire 100% of the shares of Dr. Mohammed Rashid Fakeeh Company from all existing shareholders, including Dallah Healthcare Company, for an aggregate consideration of SAR 1,595,625,000. Dallah Healthcare’s share of the total consideration amounts to SAR 497,983,407.

Completion of the Transaction is subject to a number of conditions precedent, including the non-objection of the General Authority for Competition, obtaining required approvals from certain contractual counterparties of Dr. Mohammed Rashid Al-Faqih Company, the absence of any regulatory restriction or decision prohibiting completion of the transaction.

The agreement also includes mechanisms to ensure that there is no value leakage in the target and to indemnify Dr. Soliman Abdulkader Fakeeh Hospital Company if any such leakage is confirmed. In addition, the selling shareholders provided the Buyer with number of representations, warranties and undertakings in relation to the target.

Upon completion of the transaction, an amount of SAR 100 million will be retained from the consideration and deposited into an escrow account for a specified period to cover breaches that may be identified in the target following completion.

The agreement terminates if the conditions precedent are not satisfied or waived within six months from its date of execution.

Meras Arabia Holding Company

The principal activity of Meras Arabia Holding Company is providing medical services in the field of cosmetology. The Group holds 17% in Meras Arabia Medical Holding Company and has significant influence because of the meaningful presentation on the board of the investee.

MEFIC Private Equity Opportunities Fund 3

The Fund aims to achieve long-term capital growth by investing in private equity investments in listed companies and equity-related investments within local sectors characterized by their growth prospects. Currently, the Fund has a single investment, whereby it holds 44.43% of the share capital of Meras Arabia Holding Company (Associate).

International Medical Centre Company (IMC)

The principal activity of International Medical Center Company (IMC) is the establishment, management and operation of hospitals, medical centers and health rehabilitation centers; the operation of optical centers; the management and operation of scientific research institutes and training institutes for medical and nursing services; and the operation of private hospitals.

Wahet Al-Nakheel Real Estate Fund

On 30 Jumada Al-Akhira 1446H (corresponding to 31 December 2024), the Company has entered into a Sale and Purchase Agreement (“SPA”) with Amar Al Nakheel Real Estate Company, a Special Purpose Vehicle (“SPV”) established on behalf of Wahet Al-Nakheel Real Estate Fund “The Fund”, for the transfer of undeveloped lands in the Al-Nakheel District in Riyadh owned by the Company valued at SAR 196 million as an in-kind consideration.

On 19 Ramadan 1446H (corresponding to 19 March 2025), the ownership of the lands was transferred from the Company to the fund, resulting in the recognition of capital gains amounting to SAR 51.4 million. This represents the difference between the book value of the lands and its fair value after deducting the Company's contribution percentage in the fund, which is 33.33%, these gains have been recorded in condensed consolidated interim statement of profit or loss under Other Income during the first quarter of year 2025.

The purpose of establishing the Fund is to improve the capital for the investors by the Fund through owning the lands and implementing the construction development program by developing a mixed-use project containing commercial, office, hotel, and healthcare sector spaces. According to the sale and purchase agreement and the terms and conditions of the Fund, the company will contribute the lands owned by it as an in-kind investor, Dallah Real Estate Company (a related party) will contribute the lands owned by it as an in-kind investor, and Tatweer Company contributes as a cash investor in addition to implementing the construction development program. Aljazira Capital manages the Fund. The company also contributed a cash share in the Fund of approximately SAR 8.7 million. The total capital of the Fund amounts to SAR 613 million, divided equally between the Company, Dallah Real Estate Company and Tatweer Company.

DALLAH HEALTHCARE COMPANY “A Saudi Joint Stock Company”
NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
(For the three-month period ended 31 March 2026) (unaudited)
(All amounts in Saudi Riyals unless otherwise stated)

On 27 Jumada al-Awwal 1447 AH (corresponding to 18 November 2025 AD), the company announced the launch of the Fund. The Fund has appointed Tatweer company (“Tatweer”) as the project’s real estate developer and has signed a development agreement with Tatweer worth SAR 741 million to oversee design, excavation, construction works, and the necessary regulatory approvals.

7. RELATED PARTIES - TRANSACTIONS AND BALANCES

Related parties of the Group comprise of key management personnel and associates where shareholders or the Group have control or significant influence. The Group and its related parties transact with each other as per mutually agreed terms.

Name of related parties and others	Relationship	Nature of transactions	Transactions during the period / year ended	
			31 March 2026	31 December 2025
Wahet Al-Nakheel Real Estate Fund	Associate	Mutual contribution in a real estate fund	--	204,347,685
Al-Jazira Capital	Other*	Financial Consultation	--	7,599,787
Sukkary Medical Company	Other*	Medical services	--	1,308,125
International Medical Center Company	Associate	Medicines sales	242,510	490,245
Dr Mohammed Rashid Al-Faqih Company	Associate	Technical Support and Medicines sales	96,872	2,767,955
Khalid Al-Faqih Engineering Consultation Company	Other*	Engineering Consultation	1,905,022	4,956,712
Meraas Arabia Holding Company	Associate	Medical services Dividend received	564,829 --	2,747,198 3,910,000
Adaptive TechSoft	Other*	Technical Support	2,667,121	7,416,819
Eng. Tarek Alkasabi	Chairman of Board	Management consulting	329,934	1,319,735
Dallah Trading Company	Owned partially by shareholder	Purchase of spare parts	26,093	9,737
Dareen Travel Agency	Owned partially by shareholder	Travel tickets	1,383,024	8,404,215
Dallah Al-Barakah Holding	Ultimate Parent Company	Medical services	--	175,011
Growth Path Investment Company (Mahara)	It was a major shareholder in subsidiary	Recruitment services	--	12,732,356
Joud Al Hala Company	Other*	Rent	--	330,728

*Other parties comprise of those entities where key management persons or their close family members are common or those entities which have indirect shareholding. Management have disclosed it as other parties for compliance with Companies law (Article 71).

8. TRADE RECEIVABLES

	31 March 2026 (Unaudited)	31 December 2025 (Audited)
Trade receivables	1,410,705,224	1,332,049,371
Impairment loss allowance	(147,796,805)	(135,627,359)
	1,262,908,419	1,196,422,012

DALLAH HEALTHCARE COMPANY “A Saudi Joint Stock Company”
NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
(For the three-month period ended 31 March 2026) (unaudited)
(All amounts in Saudi Riyals unless otherwise stated)

Movement in the allowance for impairment during the period / year is as follows:

	31 March 2026 (Unaudited)	31 December 2025 (Audited)
Balance at the beginning of the period / year	135,627,359	83,361,188
Resulting from the acquisition of subsidiaries	--	5,180,574
Charge during the period / year	12,169,446	49,626,956
Written-off during the period / year	--	(2,541,359)
Balance at the end of the period / year	147,796,805	135,627,359

9. MURABAHA FINANCING

Movement summary of loans and borrowings during the period is as follows:

	31 March 2026 (Unaudited)	31 December 2025 (Audited)
Balance at the beginning of the period / year	3,762,582,887	1,896,855,148
Resulting from the acquisition of subsidiaries	--	731,812,056
Remeasurement *	--	(29,520,101)
Proceeds during the period / year	345,670,575	2,420,969,754
Payments made during the period / year	(249,636,928)	(1,257,533,970)
Balance at the end of the period / year	3,858,616,534	3,762,582,887

The following is the classification of Murabaha financing:

	31 March 2026 (Unaudited)	31 December 2025 (Audited)
Non-current:		
Long -term Murabaha finance	2,984,976,705	2,942,933,467
Current:		
Short-term Murabaha finance	670,110,218	615,413,564
Current portion of long-term Murabaha finance	203,529,611	204,235,856
Total current Murabaha finance	873,639,829	819,649,420
Total Murabaha financing	3,858,616,534	3,762,582,887

Murabaha financing agreements with local banks

The Group has Murabaha finance contracts with local banks at a mark-up rate of SAIBOR plus agreed margin on facilities obtained. Murabaha contracts are denominated in Saudi Riyals and bear financial cost based on prevailing market price. Murabaha contracts are obtained to finance the operation and construction of new medical facilities and hospitals under construction and working capital financing.

As at 31 March 2026, the Group has bank Murabaha facilities of SR 6,235 million (31 December 2025: SR 6,235 million), out of which an amount of SR 3,417 million was utilized as at 31 March 2026 (31 December 2025: SR 3,321 million).

Bank Murabaha Facilities secured by promissory notes as at 31 March 2026, with a total of SR 6,358 million (31 December 2025: SR 6,358 million). In addition, the facilities secured by mortgage deed of lands, property and equipment for Al-Salam medical services company “Currently named Dallah Al Khobar hospital company” and Al-Ahsa medical services company.

* Following the acquisition of Al-Salam Medical Services Company “Currently named Dallah Al Khobar hospital company” (subsidiary) and during the third quarter of year 2025, the Group renegotiated certain contractual terms of a Murabaha financing in the subsidiary, which resulted in a reduction of the recognized financial liability. The financing was remeasured based on the revised future cash flows under the new contractual terms, resulting in the recognition of a gain of SAR 29.5 million.

Murabaha financing agreements with the Ministry of Finance

On 25 Muharram 1443H (corresponding to 02 September 2021), the Company signed an agreement with the Ministry of Finance to obtain long term loan amounting to SR 357 million for the period of 10 years (16 semi-annual installments) to support the Group’s strategy in completing the construction of Dallah Namar Hospital. The long-term loan has been secured by two promissory notes and mortgage deed of land for Dallah Namar Hospital. Out of these loans, SR 332 million has been received till 31 March 2026 (31 December 2025: SR 332 million).

On 17 Shawal 1439H (corresponding to 01 July 2018), Al-Salam medical services company “Currently named Dallah Al Khobar hospital company” signed an agreement with the Ministry of Finance to obtain long term loan amounting to SR 194 million for the period of 25 years (20 annual installments) to construct a Hospital in Al Khobar. The loan has been secured by mortgage deed of the land of the hospital. Out of which an amount of SR 110 million was utilized as at 31 March 2026 (31 December 2025: SR 110 million).

Bank covenants

The Group is subject to certain bank covenants which are fully compliant at reporting date.

DALLAH HEALTHCARE COMPANY “A Saudi Joint Stock Company”
NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
(For the three-month period ended 31 March 2026) (unaudited)
(All amounts in Saudi Riyals unless otherwise stated)

10. ZAKAT

The following table shows the movement summary of provision for zakat for the period / year ended in:

	31 March 2026 (Unaudited)	31 December 2025 (Audited)
Balance at the beginning of the period / year	21,928,027	34,816,596
Resulting from the acquisition of subsidiaries	--	4,942,206
Charge for the company and its subsidiaries companies during the period / year	5,351,330	21,490,789
Reversal for the company and its subsidiaries companies during the period/year*	(2,650,000)	(12,500,000)
Total amounts charged during the period /year	2,701,330	8,990,789
Payments made during the period /year	--	(26,821,564)
Balance at the end of the period /year	24,629,357	21,928,027

The Group has obtained zakat certificates from Zakat, Tax and Customs Authority “ZATCA” for prior years up to the year ended 31 December 2025.

*The Company received revised zakat assessments from ZATCA for the years 2019 and 2020 in the amount of SAR 12.5 million. The years 2021, 2022, and 2023 were also under review. The Company submitted revised zakat returns for all those years in accordance with the new zakat regulations which was issued on 29 February 2024, and provided the supporting documentation to the ZATCA. Following the ZATCA’s review of these years, the Company received official confirmations indicating that there were no additional zakat liabilities for those years. Accordingly, the previously recorded additional provisions related to those years, amounting to SAR 12.5 million, were reversed during the second quarter of year 2025.

The year 2024 remains under review by ZATCA, and the Company continues to submit supporting documentation to ZATCA.

During the period ended 31 March 2026, the Group reversed a Zakat provision amounting to SAR 2.65 million, as a result of the consolidation of subsidiaries under the Group’s consolidated Zakat return.

11. REVENUE

Timing of revenue recognition

	For the three-month period ended	
	31 March 2026 (Unaudited)	31 March 2025 (Unaudited)
Over time	359,436,270	283,134,792
At a point in time	653,825,998	549,618,022
	1,013,262,268	832,752,814

The revenues recorded during the period are after deducting medical rejections and other discounts. All revenue earned by the Group are within Kingdom of Saudi Arabia region. For revenue classification please refer to note (14)

Contract balances

	31 March 2026 (Unaudited)	31 December 2025 (Audited)
Trade receivables (Note 8)	1,262,908,419	1,196,422,012
Unbilled revenue *	13,296,958	8,926,101

*Unbilled revenue represents services that had been provided but still not invoiced.

12. BASIC AND DILUTED EARNINGS PER SHARE

Basic earnings per share (“EPS”) is calculated by dividing the profit for the period attributable to ordinary equity holders of the Group by the weighted average number of ordinary shares outstanding during the period.

The diluted earnings per share is same as the basic earnings per share as the Group does not have any dilutive equity instruments and as a result diluted EPS is equal to the basic EPS For the three-month periods ended 31 March 2026 and 31 March 2025.

	For the three-month period ended 31 March	
	2026 (Unaudited)	2025 (Unaudited)
Profit for the period, attributable to the ordinary shareholder	84,520,943	155,560,410
Weighted average number of ordinary shares	101,074,919	97,644,973
Basic and diluted earnings per share	0.84	1.59

13. CONTINGENCIES AND COMMITMENTS

Capital commitments

The Group had capital commitments relate construction contracts and expansion of healthcare facilities amounting to SR 416 million as at 31 March 2026 (31 December 2025: SR 490 million).

Contingent liabilities

- 1) The Group as at 31 March 2026 has potential liabilities in the form of bank guarantees amounting to SR 64 million issued on behalf of the Group in the ordinary course of business (31 December 2025: SR 60 million).
- 2) There are Letter of credits issued by the Group as at 31 March 2026 amounting to SR 25 million (31 December 2025: SR 26 million).

14. OPERATING SEGMENTS

As the operations of the Group are conducted in the Kingdom of Saudi Arabia, accordingly, for management purposes, the Group is organized into business units based on its products and services and has two reportable segments. Operating segments is determined based on the Group’s internal reporting to the Chief Operating Decision Maker (“CODM”). The CODM has been determined to be the Chief Executive Officer as he is primarily responsible for the allocation of resources to segments and the assessment of the performance of each of the segments. The CODM uses underlying income as reviewed at monthly Executive Committee and Performance meetings as the key measure of the segments’ results as it reflects the segments’ performance for the period under evaluation. Revenue and segment profit is a consistent measure within the Group.

The identified key segments identified for the group as follow:

- Medical Facilities and Pharmacies: include the operations of hospitals, clinics, and both inpatient and outpatient pharmacies.
- Distribution of Pharmaceutical Products: include the activities of marketing and distributing medicines and pharmaceutical products.

Also, the revenue disclosed geographically.

Information regarding the Group’s reportable segments is presented below:

Based on nature of services:

For the period ended 31 March 2026 (Unaudited)	Medical Facilities and Pharmacies	Distribution of Pharmaceutical Products	Total (Unaudited)
Revenues from service in Medical Facilities	747,630,673	--	747,630,673
Revenues from sale of pharmaceutical products in medical facilities and pharmacies	225,447,774	--	225,447,774
Revenues from Pharmaceutical Product Distribution	--	40,183,821	40,183,821
Total	973,078,447	40,183,821	1,013,262,268
Cost of revenue	(658,611,722)	(20,567,923)	(679,179,645)
Gross profit	314,466,725	19,615,898	334,082,623
Operating expenses	(204,787,959)	(19,572,412)	(224,360,371)
Other income, net	10,359,198	275,701	10,634,899
Operating profit	120,037,964	319,187	120,357,151
Finance cost	(42,533,988)	(737,654)	(43,271,642)
Share of results from equity accounted investees	10,896,997	--	10,896,997
Zakat	(2,611,330)	(90,000)	(2,701,330)
Net profit / (loss) for the period	85,789,643	(508,467)	85,281,176
As at 31 March 2026			
Total assets	9,118,591,539	193,505,275	9,312,096,814
Total liabilities	5,094,714,811	78,104,370	5,172,819,181

DALLAH HEALTHCARE COMPANY “A Saudi Joint Stock Company”
NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
(For the three-month period ended 31 March 2026) (unaudited)
(All amounts in Saudi Riyals unless otherwise stated)

For the period ended 31 March 2025 (Unaudited)	Medical Facilities and Pharmacies	Distribution of Pharmaceutical Products	Total (Unaudited)
Revenues from service in Medical Facilities	581,017,517	--	581,017,517
Revenues from sale of pharmaceutical products in medical facilities and pharmacies	209,216,177	--	209,216,177
Revenues from Pharmaceutical Product Distribution	--	42,519,120	42,519,120
Total	790,233,694	42,519,120	832,752,814
Cost of revenue	(510,611,194)	(24,531,791)	(535,142,985)
Gross profit	279,622,500	17,987,329	297,609,829
Operating expenses	(161,899,329)	(15,773,919)	(177,673,248)
Other income, net	57,577,585	377,278	57,954,863
Operating profit	175,300,756	2,590,688	177,891,444
Finance cost	(25,544,440)	(650,820)	(26,195,260)
Share of results from equity accounted investees	9,100,144	--	9,100,144
Zakat	(3,935,692)	(90,000)	(4,025,692)
Net profit for the period	154,920,768	1,849,868	156,770,636
As at 31 March 2025			
Total assets	8,340,499,378	203,230,617	8,543,729,995
Total liabilities	4,153,425,483	46,145,346	4,199,570,829

All of the Group's operating assets and principal markets of activity are located in the Kingdom of Saudi Arabia.

Revenue by geographic segment:	Central Region	West Region	East Region	Total
For the period ended 31 March 2026 (Unaudited)	737,481,188	83,756,357	192,024,723	1,013,262,268
For the period ended 31 March 2025 (Unaudited)	742,228,395	72,252,410	18,272,009	832,752,814

15. DIVIDENDS

Subsequent to the financial statements, on 21 Dhu Al-Qi'dah 1447H (corresponding to 08 May 2026), the Company's Board of Directors decided to distribute interim dividends to shareholders of SR 0.5 per share, amounting to SR 50,483,475. These dividends will be paid on 18 Dhu al-Hijjah 1447H (corresponding to 04 June 2026).

On 15 Ramadan 1447 H (corresponding to 04 March 2026), the Company's Board of Directors decided to distribute interim dividends to shareholders of SR 0.5 per share, amounting to SR 50,551,474. These dividends were paid on 19 Shawal 1447H (corresponding to 07 April 2026).

On 17 Ramadan 1446 H (corresponding to 17 March 2025), the Company's Board of Directors decided to distribute interim dividends to shareholders of SR 0.5 per share, amounting to SR 50,598,609. These dividends were paid on 22 Shawal 1446H (corresponding to 20 April 2025).

16. NON-CASH TRANSACTIONS

The non-cash transactions are as the following:

	Note	For the period ended 31 March 2026	For the period ended 31 March 2025
Transfer from construction work in progress to property and equipment		957,666	275,400
Transfer from asset held for sale to equity accounted investees	6	--	118,500,000
Transfer from property and equipment to intangible assets	5	440,000	3,672,278
Additions to right of use assets		3,643,555	9,789,891
Addition to lease liabilities		3,903,916	9,481,187
Increase in share capital due to business combination	1, 2d	--	38,936,030
Increase in share premium due to business combination	1, 2d	--	448,543,066

17. FINANCIAL RISK MANAGEMENT

The risk management framework and policies of the Group are consistent with those used and disclosed in the annual consolidated financial statements of the Group for the year ended 31 December 2025.

18. APPROVAL OF THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

These condensed consolidated interim financial statements were authorized for issue by the Group's Board of Directors on 21 Dhu Al-Qi'dah 1447H (corresponding to 08 May 2026).